Effect of peripherally-injected glucagon-like peptide-1 on gastric mucosal blood flow

No Thumbnail Available

Date

2009-10-09

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

The aim of this study was to investigate the mechanisms involved in the effect of glucagon-like peptide-1 (GLP-1) on the decrease in gastric mucosal blood flow (GMBF) induced by intragastric ethanol. After preparation of the stomach for GMBF recording, a probe was placed to the gastric mucosa and basal GMBF recordings were obtained by a laser Doppler flowmeter after a 30-minute stabilization period. Following GLP-1 (1000 ng/kg; i.p.) injection, 1 ml of absolute ethanol was applied to the gastric chamber and GMBF was recorded continuously during a 30-minute period. GLP-1 (1000 ng/kg; i.p.) prevented the decrease in GMBF induced by ethanol. Nitric oxide (NO) synthase inhibitor L-NAME, (30 mg/kg; s.c.), calcitonine gene-related peptide (CGRP) receptor antagonist CGRP-(8-37) (10 mu g/kg; i.p.), and cyclooxygenase inhibitor indomethacin (5 mg/kg; i.p.) all inhibited the GMBF-improving effect of GLP-1. We concluded that, NO, CGRP and prostaglandins may be involved in the effect of peripherally-injected GLP-1 on GMBF reduction induced by intraluminal ethanol.

Description

Keywords

CGRP-(8-37), Ethanol, Gastric mucosal blood flow, GLP-1, Indomethacin, L-NAME, Gene-related peptide, Experimental-models, Glp-1, Ethanol, Rat, System, Amide, Somatostatin, Involvement, Mechanisms, Endocrinology & metabolism, Physiology

Citation

İşbil, N. B. vd. (2009). "Effect of peripherally-injected glucagon-like peptide-1 on gastric mucosal blood flow". Regulatory Peptides, 157(1-3), 72-75.